- Home
- NATR vs GOSS Comparison
NATR vs GOSS Comparison
Compare NATR & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NATR
- GOSS
- Stock Information
- Founded
- NATR 1972
- GOSS 2015
- Country
- NATR United States
- GOSS United States
- Employees
- NATR N/A
- GOSS N/A
- Industry
- NATR Biotechnology: Pharmaceutical Preparations
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- NATR Health Care
- GOSS Health Care
- Exchange
- NATR Nasdaq
- GOSS Nasdaq
- Market Cap
- NATR N/A
- GOSS 212.9M
- IPO Year
- NATR N/A
- GOSS 2019
- Fundamental
- Price
- NATR $15.00
- GOSS $0.81
- Analyst Decision
- NATR Strong Buy
- GOSS Strong Buy
- Analyst Count
- NATR 2
- GOSS 5
- Target Price
- NATR $19.50
- GOSS $9.20
- AVG Volume (30 Days)
- NATR 42.4K
- GOSS 2.3M
- Earning Date
- NATR 11-07-2024
- GOSS 11-07-2024
- Dividend Yield
- NATR N/A
- GOSS N/A
- EPS Growth
- NATR 114.95
- GOSS N/A
- EPS
- NATR 0.88
- GOSS N/A
- Revenue
- NATR $445,095,000.00
- GOSS $105,322,000.00
- Revenue This Year
- NATR $2.07
- GOSS N/A
- Revenue Next Year
- NATR $2.62
- GOSS N/A
- P/E Ratio
- NATR $17.44
- GOSS N/A
- Revenue Growth
- NATR 1.36
- GOSS N/A
- 52 Week Low
- NATR $10.81
- GOSS $0.50
- 52 Week High
- NATR $21.72
- GOSS $1.60
- Technical
- Relative Strength Index (RSI)
- NATR 42.45
- GOSS 49.87
- Support Level
- NATR $14.90
- GOSS $0.76
- Resistance Level
- NATR $15.88
- GOSS $0.88
- Average True Range (ATR)
- NATR 0.62
- GOSS 0.08
- MACD
- NATR -0.21
- GOSS 0.01
- Stochastic Oscillator
- NATR 5.24
- GOSS 30.48
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.